1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.

NEUP
Neuphoria Therapeutics Inc.US flagNASDAQ Global Market
3.40
USD
+0.09
- -
18.40MMarket Cap

Total Valuation

Neuphoria Therapeutics Inc. carries a market capitalization of 18.40M, placing it among publicly traded companies globally. Its enterprise value stands at 14.35M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap18.40M
Enterprise Value14.35M

Share Statistics

Neuphoria Therapeutics Inc. currently has 5.41M shares outstanding.

Shares Outstanding5.41M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Neuphoria Therapeutics Inc. trades at a trailing price-to-earnings ratio of 19.03. The price-to-sales ratio is 21.87, and the price-to-book ratio stands at 1.39.

PE Ratio19.03
PS Ratio21.87
PB Ratio1.39
P/TBV Ratio2.02
P/FCF Ratio-2.08
P/OCF Ratio-2.08

Enterprise Valuation

The EV/Sales ratio of 12.22 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.75 provides insight into valuation relative to core operating earnings.

EV / Sales12.22
EV / EBITDA1,655.57
EV / EBIT19.75
EV / FCFN/A

Financial Position

Neuphoria Therapeutics Inc. maintains a current ratio of 27.85, meaning it holds 27.9x the short-term assets needed to cover near-term liabilities.

Current Ratio27.85
Quick Ratio27.33
Debt / Equity0.14
Debt / EBITDA0.00
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-63.92
Return on Assets (ROA)-47.74
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax-139,173.00
Effective Tax RateN/A

Stock Price Statistics

Neuphoria Therapeutics Inc.'s stock has declined approximately -77.92208% over the past 52 weeks. The 50-day moving average sits at 3.67, while the 200-day moving average is 4.19.

Beta (5Y)N/A
52-Week Price Change-77.92208%
50-Day Moving Average3.67
200-Day Moving Average4.19
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Neuphoria Therapeutics Inc. generated 1.17M in revenue and converted that into -13.45M in net income, yielding earnings per share of -3.31. EBITDA reached -8.35M, while operating income came in at -9.01M.

Revenue1.17M
Gross ProfitN/A
Operating Income-9.01M
Pretax Income-13.59M
Net Income-13.45M
EBITDA-8.35M
EBIT-9.01M
Earnings Per Share (EPS)-3.31

Balance Sheet

Neuphoria Therapeutics Inc. holds 19.87M in cash and equivalents against 34,345.00 in total debt, resulting in a net debt position of -19.83M. Total book value stands at 24.60M, with working capital of 20.31M providing operational flexibility.

Cash & Cash Equivalents19.87M
Total Debt34,345.00
Net Debt-19.83M
Equity (Book Value)24.60M
Book Value Per Share4.55
Working Capital20.31M

Cash Flow

Neuphoria Therapeutics Inc. produced -12.35M in operating cash flow over the past twelve months.

Operating Cash Flow-12.35M
Capital ExpendituresN/A
Free Cash Flow-12.35M
FCF Per Share-3.04

Margins

Neuphoria Therapeutics Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -767.32 and net profit margin of -1,145.66 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-767.32
Pretax Margin-1,157.51
Profit Margin-1,145.66
EBITDA Margin-710.86

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-52.41
FCF Yield-48.11

Stock Splits

Neuphoria Therapeutics Inc.'s most recent stock split took place on December 24, 2024 with a 12:1 split ratio.

Last Split Date12/24/2024
Split Ratio12:1

Scores

Neuphoria Therapeutics Inc. posts an Altman Z-Score of -7.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-7.95